Trial Profile
A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (Morpheus-panBC)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 14 Aug 2026
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Capecitabine (Primary) ; Cobimetinib (Primary) ; Inavolisib (Primary) ; Ipatasertib (Primary) ; Ladiratuzumab-Vedotin (Primary) ; Selicrelumab (Primary) ; Tocilizumab (Primary) ; Abemaciclib; Atirmociclib; Carboplatin; Empagliflozin; Eribulin; Fulvestrant; Gemcitabine; Giredestrant; Letrozole; Metformin; Paclitaxel; Palbociclib; Ribociclib; Sacituzumab govitecan
- Indications Adenocarcinoma; Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms Morpheus-panBC
- Sponsors Genentech; Roche
Most Recent Events
- 17 Jun 2026 The protocol has been amended to include an increase in cohorts from 6 to 7, an expansion of treatment arms from 19 to 23, a revision to the planned enrollment, the addition of Giredestrant as a treatment, and an update to the timeframe of the primary endpoint, Objective Response Rate (ORR).
- 17 Jun 2026 Planned number of patients changed from 792 to 1132.
- 28 Nov 2025 Number of treatment arms are increased from 16 to 19 by the addition of 3 more experimental arms comprising new drug combinations with Fulvestrant, Empagliflozin ,Atirmociclib, Palbociclib and metformin.